Table 4.

Studies on the prognostic role of TS status in gastric cancer

ReferenceNo. patientsChemotherapySettingTS analysisResults
Ichikawa (28)53S1PalliativeIHCHigh TS expression correlated with adverse outcome
Grau (29)76TegafurAdjuvantIHCHigh TS expression correlated with adverse outcome
Tahara (30)385FU/MTXPalliativeIHCNo prognostic influence
Choi (31)1035FU/DoxoAdjuvantIHCNo prognostic influence
Suda (32)675FUAdjuvantIHCHigh TS expression correlated with adverse outcome
Miyamoto (33)41S1PalliativeIHCNo prognostic influence
Tsujitani (34)213Observation/5FUAdjuvantIHCHigh TS expression correlated with adverse outcome in 5FU treated and untreated patients
Kuniyasu (35)1345FUAdjuvant/palliativeIHCHigh TS expression correlated with adverse outcome
Boku (36)395FU/DDPPalliativeIHCHigh TS expression correlated with adverse outcome
Yeh (37)305FUPalliativeIHCHigh TS expression correlated with adverse outcome
Toriumi (38)225FUPalliativeGenotype/mRNA*No prognostic influence
Ishikawa (39)41Observation/5FUPalliativemRNA/EAHigh mRNA levels correlated with adverse outcome in stage III/IV
Metzger (40)385FU/DDPPreoperativemRNANo prognostic influence of high mRNA levels
Lenz (41)655FU/DDPPreoperativemRNAHigh mRNA levels correlated with adverse outcome
Terashima (42)81Observation/5FUAdjuvantEAHigh EA levels correlated with adverse outcome in untreated patients
Ishida (20)115Observation/5FUAdjuvantGenotype*Adverse outcome for 3R/3R carriers (nonsignificant trend in the subgroup of 5FU patients)
  • Abbreviations: 5FU, 5-fluorouracil; MTX, methotrexate; Doxo, doxorubicin; DDP, cisplatin; IHC, immunohistochemistry; EA, TS enzymatic activity.

  • * Analysis of the TS 5′-UTR VNTR polymorphism (2R versus 3R carriers).